The Life Sciences team advised C4 Therapeutics, Inc. (Nasdaq: CCCC) on its upsized initial public offering for gross proceeds of $209.76 million, before deducting underwriting discounts and commissions and other offering expenses. The company sold 11,040,000 shares of its common stock, including shares sold pursuant to the full exercise of the underwriters’ option to purchase additional shares, at a price to the public of $19.00 per share. The transaction closed on October 6, 2020.

C4 Therapeutics, Inc. is a biopharmaceutical company focused on harnessing the body’s natural regulation of protein levels to develop novel therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions and other diseases.

Goodwin has represented the company from its $73 million Series A financing and collaboration with Roche at its inception in 2016, its collaboration with Biogen last year, and most recently, its $170 million Series B financing earlier this year.  

The bi-coastal Goodwin deal team was led by Lawrence Wittenberg, Edwin O’Connor and Shoaib  Ghias, and included Rob Intile, Jr.Julie Tibbets, Roger A. Cohen, Sarah Bock, L. Morgan Frisoli, Daniel Karelitz, Leon Peschel, Tim Holahan, James Matarese and Nathan Needle.

For additional details on the offering, please read the closing press release.